Sign in

You're signed outSign in or to get full access.

BT

BioXcel Therapeutics, Inc. (BTAI)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 was operationally focused on the SERENITY At‑Home Phase 3 data and sNDA planning; financials remained modest with IGALMI® product revenue of $0.10M and net loss of $30.9M as derivative liability mark‑to‑market increased the loss beyond operating levels .
  • Both revenue and EPS missed S&P Global consensus: Revenue $0.10M vs $0.22M consensus; EPS −$2.18 vs −$1.34 consensus; misses were driven by minimal commercial spend and continued R&D investment ahead of at‑home label expansion plans; derivative liability losses further widened GAAP EPS bolding the miss on EPS and revenue. Values retrieved from S&P Global.*
  • Management expects to submit an sNDA in early Q1 2026 for IGALMI at‑home use (bipolar/schizophrenia), and highlighted a substantially larger at‑home TAM (57–77M annual episodes vs prior 23M), a key future stock catalyst upon FDA acceptance/approval .
  • Safety/tolerability from SERENITY At‑Home were positive: no drug‑related SAEs, syncopes or falls; consistent tolerability with repeat dosing; and an exploratory efficacy signal via mCGI‑S reduction, supporting viability of home use .

What Went Well and What Went Wrong

What Went Well

  • SERENITY At‑Home Phase 3 showed strong safety/tolerability and repeat‑dose consistency with no drug‑related SAEs, syncopes, or falls; most TEAEs were mild .
  • Exploratory efficacy: BXCL501 demonstrated mean mCGI‑S reduction vs placebo at 2 hours with continued effects and benefit on repeat dosing, and a supporting correlation study validated mCGI‑S assessment approach .
  • Management sharpened the regulatory path, guiding for an early Q1 2026 sNDA submission and emphasized commercialization readiness initiatives: “We are focused on the next phase of our journey, preparing for an sNDA submission and advancing pre‑launch and commercial readiness activities” — Vimal Mehta, CEO .

What Went Wrong

  • IGALMI revenue declined to $0.10M in Q3 2025 (vs $0.21M YoY), reflecting minimal commercial resources and strategic reprioritization, limiting near‑term scale .
  • GAAP net loss widened to $30.9M (vs $13.7M YoY) largely due to $12.5M unrealized losses on derivative liabilities; operating loss remained high at $14.2M .
  • Cash usage increased to $18.8M in operating cash burn during the quarter, necessitating additional ATM raises ($4.9M post quarter‑end); forward‑looking disclosures continue to flag funding and going‑concern risks .

Financial Results

Income Statement Trends (USD Thousands unless noted)

MetricQ3 2024Q1 2025Q2 2025Q3 2025
Product Revenues ($)$214 $168 $120 $98
Cost of Goods Sold ($)$1,170 $14 $107 $11
Operating Loss ($)$(15,293) $(10,099) $(15,852) $(14,228)
Net Loss ($)$(13,650) $(7,254) $(19,187) $(30,911)
Diluted EPS ($)$(5.15) $(1.50) $(2.45) $(2.18)

Notes:

  • Q3 2025 net loss includes $12.5M unrealized losses tied to derivative liabilities; Q3 2024 benefited from $4.8M gains .
  • No explicit non‑GAAP measures reported; GAAP results reflect derivative liability volatility .

Balance Sheet and Liquidity

MetricQ3 2024Q1 2025Q2 2025Q3 2025
Cash & Cash Equivalents + Restricted Cash ($)$29,854 $31,013 $18,575 $37,320
Total Assets ($)$38,338 $38,566 $25,789 $44,792
Total Liabilities ($)$131,439 $128,738 $133,456 $133,711
Stockholders’ Equity (Deficit) ($)$(93,101) $(90,172) $(107,667) $(88,919)
Operating Cash Used ($)—$(12,000) $(12,600) $(18,800)

Post quarter‑end: Raised $4.9M via ATM program .

Actuals vs S&P Global Consensus (Q3 2025)

MetricActualConsensusBeat/Miss
Revenue ($USD Millions)$0.10 $0.22*— Miss
Primary EPS ($USD)$(2.18) $(1.34)*— Miss

Values retrieved from S&P Global.*

KPIs and Clinical Execution

KPIQ1 2025Q2 2025Q3 2025
SERENITY At‑Home: Patients Randomized—>200 enrolled 246 randomized
SERENITY At‑Home: Episodes Collected—>2,200 episodes 2,628 episodes
Safety Signals (SAEs/syncopes/falls)—DSMB favorable recs None reported (drug‑related); most TEAEs mild
Exploratory Efficacy——mCGI‑S reduction vs placebo at 2 hours

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
IGALMI At‑Home sNDA Submission TimingRegulatory“Potential sNDA submission” post FDA meeting (Aug 2025) Early Q1 2026 submission expected Clarified/Updated timeline
At‑Home TAM (Episodes/yr, U.S.)Market23M episodes (historic claims) 57–77M episodes based on trial frequency research Raised materially
TRANQUILITY In‑Care (Alzheimer’s Agitation)ClinicalPreparing for initiation FDA protocol feedback; CRO proposals under evaluation Progressing toward initiation
Commercial Posture (Institutional IGALMI)2025“Minimal commercial resources” Continuing supply and brand awareness with minimal resources Maintained

Earnings Call Themes & Trends

Note: A Q3 2025 earnings call transcript was not available via our document tools; themes are synthesized from company press releases.

TopicPrevious Mentions (Q1/Q2)Current Period (Q3)Trend
Regulatory Path (sNDA for At‑Home)Enrollment complete; topline expected H2’25; FDA meeting planned sNDA submission expected early Q1 2026 Visibility improved; near‑term filing
TAM Expansion23M at‑home episodes (claims‑based) 57–77M episodes based on heightened frequency data Materially higher TAM
Safety/TolerabilityDSMB favorable; broad trial completion No drug‑related SAEs/syncopes/falls; mild TEAEs; repeat‑dose consistency Stronger safety narrative
Exploratory Efficacy—mCGI‑S reduction vs placebo at 2 hours; supporting correlation study Positive signal supporting at‑home use
R&D ExecutionAdvancing SERENITY and TRANQUILITY CRO proposals; FDA protocol feedback for TRANQUILITY Steady progress to Phase 3 Alzheimer’s
Commercial PostureMinimal resources; institutional presence Continuing minimal commercial effort Maintained pending label expansion

Management Commentary

  • “We are focused on the next phase of our journey, preparing for an sNDA submission and advancing pre‑launch and commercial readiness activities.” — Vimal Mehta, Ph.D., CEO .
  • “BXCL501 has the potential to redefine the treatment of agitation, addressing an at‑home market opportunity of 57 to 77 million annual episodes in the U.S. alone.” — Vimal Mehta, Ph.D., CEO .
  • Safety/tolerability highlights: no drug‑related SAEs, syncopes or falls; consistent tolerability with repeat dosing; most TEAEs mild .
  • Financial discipline: maintaining cash runway in support of sNDA and milestones, with ATM proceeds post quarter‑end .

Q&A Highlights

A full Q3 2025 earnings call transcript was not available via our tools; key clarifications reflected in the press release:

  • Safety profile and tolerability (no drug‑related SAEs/syncopes/falls; mild TEAEs; repeat‑dose consistency) underpin suitability for home use .
  • Expanded TAM estimate (57–77M episodes) driven by higher observed/agreed episode frequency relative to historic claims data (23M), supporting commercial potential .
  • Regulatory timeline firmed to early Q1 2026 for sNDA submission; TRANQUILITY trial preparation advanced with FDA protocol feedback and CRO proposals .

Estimates Context

  • Q3 2025 results missed consensus: Revenue $0.10M vs $0.22M*, EPS −$2.18 vs −$1.34*; small base revenue and ongoing R&D/commercial preparatory spend plus non‑operating derivative losses pressured GAAP EPS .
  • Limited analyst coverage (3 estimates for EPS and revenue) implies potential for estimate volatility as regulatory milestones approach.*

Values retrieved from S&P Global.*

Key Takeaways for Investors

  • The at‑home IGALMI sNDA filing in early Q1 2026 is the next core catalyst; FDA acceptance would likely drive narrative re‑rating around at‑home commercialization .
  • SERENITY At‑Home safety/tolerability and exploratory efficacy support label expansion potential; positive safety is critical for repeat self‑administration in home settings .
  • TAM uplift from 23M to 57–77M episodes materially expands the long‑term commercial opportunity and could reshape sell‑side penetration models .
  • Near‑term financials remain constrained (Q3 revenue $0.10M; net loss $30.9M); derivative liability volatility can amplify GAAP EPS swings, complicating quarterly optics .
  • Liquidity improved sequentially (cash $37.3M) aided by ATM post quarter‑end; continued funding needs and going‑concern risk disclosures warrant close monitoring of capital strategy .
  • Alzheimer’s agitation (TRANQUILITY In‑Care) remains a strategic leg; protocol feedback and CRO selection indicate incremental progress toward Phase 3 execution .
  • Trading setup: focus on sNDA acceptance, label expansion timing, and any payer/provider readiness updates; estimate revisions likely as TAM and launch assumptions recalibrate post regulatory milestones .
Earnings Call Transcript status: Not found in our document corpus; we searched BTAI earnings-call-transcript and company IR sites but only press releases and filings were available [ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-third-quarter-2025-financial] **[https://www.marketbeat.com/earnings/reports/2025-11-13-bioxcel-therapeutics-inc-stock/]** **[https://capedge.com/filing/1720893/0001104659-25-109880/BTAI-10Q-2025Q3/file/2]**.

Values retrieved from S&P Global.*